循环和 thiazide 利尿剂和心力衰竭的结果与保存的喷射分数
Barna Szabó-Söderberg1, Lina Benson1, Gianluigi Savarese2
1Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
American heart journal
|May 8, 2025
概括
在心力衰竭中,保留喷射分数 (HFpEF),基线循环利尿剂的使用和更高剂量增加了心血管风险. 结合循环和 thiazide 利尿剂也会增加 HFpEF 患者的风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭与保存的喷射分数 (HFpEF) 试验经常使用基线尿剂的使用作为丰富标准.
- thiazides 和循环利尿剂剂量在 HFpEF 丰富中的特定作用仍然不清楚.
研究的目的:
- 评估基线循环和 thiazide 利尿剂的使用以及循环利尿剂的剂量对 HFpEF 患者心血管结果的影响.
主要方法:
- 对TOPCAT-美洲试验进行了后期分析.
- 评估的主要结局是心血管死亡和心力衰竭 (HHF) 的住院总数的复合.
主要成果:
- 循环利尿剂单疗法和联合循环+化物疗法与初级结局和HHF风险增加有关.
- 较高的基线循环利尿剂剂与所有研究结果的更高风险相关.
- 化物单一治疗与终点没有关联,但与循环利尿剂的联合治疗增加了风险.
结论:
- 基线循环利尿剂的使用和更高的剂量与心血管死亡和HFF在HFpEF中的增加有关.
- 单独使用 thiazide 利尿剂似乎不会增加风险,但它们添加到循环利尿剂中会增加 HFpEF 患者的风险.
相关概念视频
Heart Failure Drugs: Diuretics
291
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
291
Antihypertensive Drugs: Thiazide-Class Diuretics
446
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
446
Heart Failure Drugs: Inotropic Agents
416
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
416
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
Heart Failure Drugs: β-Blockers
273
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
273
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K


